Overview

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

Status:
Terminated

Trial end date:
2005-03-01

Target enrollment:

Participant gender:

Summary

The original objective of this study was to assess the safety and efficacy of the buprenorphine transdermal system (BTDS) (5, 10, and 20) in comparison to placebo transdermal system in subjects with moderate to severe osteoarthritis pain. However, this study was terminated early with only 35% of the planned sample size, therefore the primary objective is changed to focus on the safety evaluations.

Phase:

Phase 3

Details

Lead Sponsor:

Purdue Pharma LP

Treatments:

Analgesics, Opioid
Buprenorphine